0001613103-20-000002.txt : 20200218 0001613103-20-000002.hdr.sgml : 20200218 20200218064742 ACCESSION NUMBER: 0001613103-20-000002 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20200218 ITEM INFORMATION: Results of Operations and Financial Condition FILED AS OF DATE: 20200218 DATE AS OF CHANGE: 20200218 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Medtronic plc CENTRAL INDEX KEY: 0001613103 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 000000000 FISCAL YEAR END: 0424 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36820 FILM NUMBER: 20623371 BUSINESS ADDRESS: STREET 1: 20 ON HATCH, LOWER HATCH STREET CITY: DUBLIN STATE: L2 ZIP: 2 BUSINESS PHONE: 01135314381700 MAIL ADDRESS: STREET 1: 20 ON HATCH, LOWER HATCH STREET CITY: DUBLIN STATE: L2 ZIP: 2 FORMER COMPANY: FORMER CONFORMED NAME: Medtronic Ltd DATE OF NAME CHANGE: 20150112 FORMER COMPANY: FORMER CONFORMED NAME: Medtronic Holdings Ltd DATE OF NAME CHANGE: 20140711 FORMER COMPANY: FORMER CONFORMED NAME: Kalani I Ltd DATE OF NAME CHANGE: 20140709 8-K 1 mdt-20200218.htm 8-K mdt-20200218
0001613103Medtronic plcD02 XH02false00016131032020-02-182020-02-180001613103us-gaap:CommonStockMember2020-02-182020-02-180001613103mdt:SeniorNotes2019Due2021FloatingMember2020-02-182020-02-180001613103mdt:SeniorNotes2019Due2021Member2020-02-182020-02-180001613103mdt:SeniorNotes2019Due2022Member2020-02-182020-02-180001613103mdt:SeniorNotes2019Due20230.375PercentMember2020-02-182020-02-180001613103mdt:SeniorNotes2019Due2025Member2020-02-182020-02-180001613103mdt:SeniorNotes2019Due2027Member2020-02-182020-02-180001613103mdt:SeniorNotes2019Due20311.625PercentMember2020-02-182020-02-180001613103mdt:SeniorNotes2019Due20311.00PercentMember2020-02-182020-02-180001613103mdt:SeniorNotes2019Due20392.250PercentMember2020-02-182020-02-180001613103mdt:SeniorNotes2019Due20391.50PercentMember2020-02-182020-02-180001613103mdt:SeniorNotes2019Due2049Member2020-02-182020-02-18

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
_____________________________ 
FORM 8-K
 _____________________________ 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 18, 2020
 _____________________________ 
Medtronic Public Limited Company
(Exact name of Registrant as Specified in its Charter)
  _____________________________ 
 
Ireland 1-36820 98-1183488
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)

20 On Hatch, Lower Hatch Street
Dublin 2, Ireland
(Address of principal executive offices) (Zip Code)
+353 1 438-1700
(Registrant’s telephone number, including area code)
Not Applicable  
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))












Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Ordinary shares, par value $0.0001 per shareMDTNew York Stock Exchange
Floating Rate Notes due 2021MDT/21New York Stock Exchange
0.000% Senior Notes due 2021MDT/21ANew York Stock Exchange
0.000% Senior Notes due 2022MDT/22BNew York Stock Exchange
0.375% Senior Notes due 2023MDT/23BNew York Stock Exchange
0.25% Senior Notes due 2025MDT/25New York Stock Exchange
1.125% Senior Notes due 2027MDT/27New York Stock Exchange
1.625% Senior Notes due 2031MDT/31New York Stock Exchange
1.00% Senior Notes due 2031MDT/31ANew York Stock Exchange
2.250% Senior Notes due 2039MDT/39ANew York Stock Exchange
1.50% Senior Notes due 2039MDT/39BNew York Stock Exchange
1.75% Senior Notes due 2049MDT/49New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐





Item 2.02.Results of Operations and Financial Condition

On February 18, 2020, Medtronic plc, a public limited company organized under the laws of Ireland, issued a press release announcing its third quarter fiscal year 2020 financial results. A copy of the press release is furnished as Exhibit 99.1 to this report.
 
Item 9.01.      Exhibits.
(d) List of Exhibits







SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
   MEDTRONIC PUBLIC LIMITED COMPANY
  By /s/ Karen L. Parkhill
Date: February 18, 2020   Karen L. Parkhill
   Executive Vice President and Chief Financial Officer






EXHIBIT INDEX



 EX-99.1 2 exhibit991-fy20q3earni.htm EX-99.1 Document

Exhibit 99.1
 
mdtlogo2a951.jpg
  NEWS RELEASE
 
 Contacts:  
 Erika Winkels  Ryan Weispfenning
 Public Relations  Investor Relations
 +1-763-526-8478  +1-763-505-4626

FOR IMMEDIATE RELEASE

MEDTRONIC REPORTS THIRD QUARTER FINANCIAL RESULTS

▪Revenue of $7.7 Billion Increased 2.3% Reported and 2.6% Organic
▪GAAP Diluted EPS of $1.42 Increased 51%; Non-GAAP Diluted EPS of $1.44 Increased 12%
▪Cash Flow from Operations of $2.4 Billion Increased 17%; Free Cash Flow of $2.1 Billion Increased 21%
▪Company Raises Full Year EPS Guidance

DUBLIN – February 18, 2020 – Medtronic plc (NYSE:MDT) today announced financial results for its third quarter of fiscal year 2020, which ended January 24, 2020.

The company reported third quarter worldwide revenue of $7.717 billion, an increase of 2.3 percent as reported and 2.6 percent on an organic basis, which adjusts for a $46 million negative impact from foreign currency and a $21 million contribution from the company’s acquisition of Titan Spine, which is reported in the Spine division in the Restorative Therapies Group. As reported, third quarter GAAP net income and diluted earnings per share (EPS) were $1.915 billion and $1.42, respectively. As detailed in the financial schedules included through the link at the end of this release, third quarter non-GAAP net income and non-GAAP diluted EPS were $1.949 billion and $1.44, respectively, increases of 11.3 percent and 11.6 percent, respectively.

Third quarter U.S. revenue of $4.021 billion represented 52 percent of company revenue and increased 0.5 percent as reported. Non-U.S. developed market revenue of $2.377 billion represented 31 percent of company revenue and increased 0.4 percent as reported and 1.5 percent constant currency. Emerging Markets revenue of $1.318 billion represented 17 percent of company revenue and increased 12.0 percent as reported and 13.6 percent constant currency.

“Organic revenue growth was light this quarter, due largely to transient issues,” said Omar Ishrak, Medtronic chairman and chief executive officer. “However, we continue to feel very good about the fourth quarter, and in the third quarter, a softer top-line was more than offset by significant margin expansion, resulting in better-than-expected earnings per share and free cash flow.”

Cardiac and Vascular Group
The Cardiac and Vascular Group (CVG) includes the Cardiac Rhythm & Heart Failure (CRHF), Coronary & Structural Heart (CSH), and Aortic, Peripheral & Venous (APV) divisions. CVG third quarter revenue of $2.819 billion increased 1.2 percent as reported and 1.8 percent constant currency. CVG’s lower-than-expected revenue growth this quarter reflected customers holding back purchases ahead of new product launches in CRHF, a slower-than-expected recovery in left ventricular assist devices (LVADs), and below-market growth in U.S. transcatheter aortic valves (TAVR). CVG’s performance was driven by mid-single digit growth in CSH and low-single digit growth in APV, offset by flat results in CRHF, all on a constant currency basis.

1

▪Cardiac Rhythm & Heart Failure revenue of $1.393 billion decreased 0.3 percent as reported and increased 0.3 percent constant currency. Arrhythmia Management grew in the low-single digits, driven by high-single digit growth in Pacemakers on the continued adoption of the company’s Micra™ transcatheter pacing system, as well as high-single digit growth in AF Solutions, all on a constant currency basis. Arrhythmia Management growth was offset by low-double digit declines in implantable defibrillators (ICDs) ahead of new product launches. Heart Failure declined low-single digits on a constant currency basis, reflecting declines in replacement devices of cardiac resynchronization therapy defibrillators (CRT-Ds) and left ventricular assist devices (LVADs).

▪Coronary & Structural Heart revenue of $948 million increased 3.8 percent as reported and 4.6 percent constant currency, led by mid-teens constant currency growth in TAVR, reflecting continued expansion into the low risk patient population. TAVR growth was offset by low-single digit declines in drug-eluting stents.

▪Aortic, Peripheral & Venous revenue of $478 million increased 0.4 percent as reported and 1.1 percent constant currency. Aortic grew in the mid-single digits, driven by high-single digit growth in thoracic aortic stent grafts and mid-single digit growth in abdominal aortic stent grafts, all on a constant currency basis. Aortic growth was offset by high-single digit constant currency declines in Peripheral, reflecting mid-thirties constant currency declines in drug-coated balloons. Venous grew mid-single digits on a constant currency basis on the strength of the company’s VenaSeal™ Closure System.

Minimally Invasive Therapies Group
The Minimally Invasive Therapies Group (MITG) includes the Surgical Innovations (SI) and the Respiratory, Gastrointestinal & Renal (RGR) divisions. MITG third quarter revenue of $2.176 billion increased 2.4 percent as reported and 3.2 percent constant currency. MITG’s lower-than-expected revenue growth this quarter was due to the upgrade of its enterprise resource planning (ERP) system in the U.S. and Canada, which was completed in the quarter. The upgrade and the resulting issues that affected MITG’s performance in the third quarter are now fully resolved. MITG’s revenue performance was driven by mid-single digit constant currency growth in SI and low-single digit growth in RGR.

▪Surgical Innovations revenue of $1.474 billion increased 2.8 percent as reported and 3.6 percent constant currency, reflecting the impact of the ERP system upgrade this quarter. Advanced Energy grew in the high-single digits on a constant currency basis on continued strength in sales of LigaSure™ vessel sealing instruments and Valleylab™ FT10 Energy Platform.

▪Respiratory, Gastrointestinal & Renal revenue of $702 million increased 1.7 percent as reported and 2.2 percent constant currency, reflecting the impact of the ERP system upgrade this quarter. GI Solutions grew in the low-double digits on a constant currency basis, with solid growth in Bravo™ calibration-free reflux testing systems, EndoFLIP™ imaging systems, and PillCam™ capsule endoscopy systems.

Restorative Therapies Group
The Restorative Therapies Group (RTG) includes the Brain Therapies, Spine, Specialty Therapies, and Pain Therapies divisions. RTG third quarter revenue of $2.111 billion increased 4.2 percent as reported and 3.6 percent on an organic basis, which adjusts for the negative impact from foreign currency and the positive contribution from the company’s acquisition of Titan Spine. RTG’s lower-than-expected revenue growth this quarter reflected customer buying patterns in Bone Morphogenetic Protein (BMP) and the continued market slowdown and slight share loss in Pain Stimulation ahead of its DTM™ therapy launch. RTG’s performance this quarter was driven by high-single digit growth in Brain Therapies, mid-single digit growth in Specialty Therapies, and flat results in Spine, offset by low-single digit declines in Pain Therapies, all on an organic basis.

▪Brain Therapies revenue of $795 million increased 8.6 percent as reported and 9.2 percent constant currency, reflecting mid-teens constant currency growth in Neurovascular and low-double digit constant currency growth in Neurosurgery. Neurovascular results were driven by high-single digit constant currency growth in Hemorrhagic Stroke and mid-twenties
2

growth in Ischemic Stroke. Neurosurgery had strong growth across StealthStation™ S8 surgical navigation systems, O-arm™ surgical imaging systems, Midas Rex™ MR8™ high speed drill system, and Mazor X Stealth™ Edition robotic guidance systems.

▪Spine revenue of $674 million increased 2.9 percent as reported and declined 0.2 percent on an organic basis. When combined with the company’s sales of enabling technology used in spine surgeries, including robotics, navigation, imaging, and powered surgical instruments that are recognized in the Brain Therapies division, global Core Spine revenue and U.S. Core Spine revenue both grew in the mid-single digits on an organic basis. This growth was offset by high-single digit declines in bone morphogenetic protein (BMP), driven by customer buying patterns of Infuse™ bone graft.

▪Specialty Therapies revenue of $340 million increased 4.6 percent as reported and 4.9 percent constant currency. ENT grew in the low-double digits on a constant currency basis, driven by capital equipment sales of the StealthStation™ ENT surgical navigation system, as well as sales of disposables used with the intraoperative NIM nerve monitoring system. Pelvic Health declined in the low-single digits on a constant currency basis.

▪Pain Therapies revenue of $303 million decreased 3.5 percent as reported and 3.2 percent constant currency. Pain Stimulation declined, reflecting the slowdown of the spinal cord stimulation market and slight share loss. Targeted Drug Delivery grew in the low-single digits on a constant currency basis on strong sales of the SynchroMed™ II drug infusion system.

Diabetes Group
Diabetes Group third quarter revenue of $610 million was flat as reported and increased 0.8 percent constant currency. Diabetes Group revenue performance was led by international markets, which grew 13.7 percent as reported and 15.6 percent constant currency, driven by the ongoing launch of the MiniMed™ 670G hybrid closed loop insulin pump system. International growth was offset by low-double digit declines in the U.S., owing to increased competition as the group awaits upcoming new product approvals.

Global sales of integrated continuous glucose monitoring (CGM) sensors grew in the mid-teens on a constant currency basis, driven by global adoption of sensor-augmented insulin pump systems and the resulting strong sensor attachment rates.

Guidance
The company today issued fourth quarter revenue growth guidance and raised its full year EPS guidance for fiscal year 2020.

The company indicated that it is comfortable with current Street consensus calling for fourth quarter organic revenue growth of approximately 4.5 percent and EPS of $1.64, excluding any impact from COVID-19. If current exchange rates hold, fourth quarter revenue growth would be negatively affected by 0.8 to 1.4 percent.

The company increased its fiscal year 2020 diluted non-GAAP EPS guidance from the prior range of $5.57 to $5.63 to a new range of $5.63 to $5.65, including an estimated 7 cent negative impact from foreign exchange based on current rates and excluding any impact from COVID-19. This implies fourth quarter diluted non-GAAP EPS in the range of $1.62 to $1.64, including an estimated 3 cent negative impact from foreign exchange based on current rates and excluding any impact from COVID-19.

While COVID-19 is expected to negatively affect the company’s fourth quarter financial results, the situation is fluid, and the duration and magnitude of the impact are difficult to quantify at this time. The company continues to monitor and assess business impact daily and will provide an update later in the quarter.

“We delivered robust margin expansion and free cash flow growth this quarter,” said Ishrak. “As we look ahead to the fourth quarter and fiscal year 2021, our top-line growth acceleration is on track as we begin to realize the benefits of new product launches and put the challenges of the third quarter behind us.”



3

Webcast Information
Medtronic will host a webcast today, February 18, at 8:00 a.m. EST (7:00 a.m. CST) to provide information about its businesses for the public, investors, analysts, and news media. This quarterly webcast can be accessed by clicking on the Investor Events link at investorrelations.medtronic.com and this earnings release will be archived at newsroom.medtronic.com. Medtronic will be live tweeting during the webcast on its Newsroom Twitter account, @Medtronic. Within 24 hours of the webcast, a replay of the webcast and transcript of the company’s prepared remarks will be available by clicking on the Investor Events link at investorrelations.medtronic.com.

Financial Schedules
To view the third quarter financial schedules and non-GAAP reconciliations, click here. To view the third quarter earnings presentation, click here. Both documents can also be accessed by visiting newsroom.medtronic.com.

About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements, which are subject to risks and uncertainties, including those described in Medtronic’s periodic reports and other filings with the U.S. Securities and Exchange Commission (the “SEC”). Anticipated results only reflect information available to Medtronic at this time and may differ from actual results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this press release. Certain information in this press release includes calculations or figures that have been prepared internally and have not been reviewed or audited by our independent registered public accounting firm, including but not limited to, certain information in the financial schedules accompanying this press release. Use of different methods for preparing, calculating or presenting information may lead to differences and such differences may be material.

NON-GAAP FINANCIAL MEASURES
This press release contains financial measures and guidance, including adjusted net income and adjusted diluted EPS, which are considered “non-GAAP” financial measures under applicable SEC rules and regulations. References to quarterly figures increasing, decreasing or remaining flat are in comparison to the third quarter of fiscal year 2019.

Medtronic management believes that non-GAAP financial measures provide information useful to investors in understanding the company’s underlying operational performance and trends and to facilitate comparisons with the performance of other companies in the med tech industry. Non-GAAP net income and diluted EPS exclude the effect of certain charges or gains that contribute to or reduce earnings but that result from transactions or events that management believes may or may not recur with similar materiality or impact to operations in future periods (Non-GAAP Adjustments). Medtronic generally uses non-GAAP financial measures to facilitate management’s review of the operational performance of the company and as a basis for strategic planning. Non-GAAP financial measures should be considered supplemental to and not a substitute for financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP), and investors are cautioned that Medtronic may calculate non-GAAP financial measures in a way that is different from other companies. Management strongly encourages investors to review the company’s consolidated financial statements and publicly filed reports in their entirety. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the financial schedules accompanying this press release.

Medtronic calculates forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, forward-looking organic revenue growth guidance excludes
4

the impact of foreign currency fluctuations, as well as significant acquisitions or divestitures. Forward-looking diluted non-GAAP EPS guidance also excludes other potential charges or gains that would be recorded as Non-GAAP Adjustments to earnings during the fiscal year. Medtronic does not attempt to provide reconciliations of forward-looking non-GAAP EPS guidance to projected GAAP EPS guidance because the combined impact and timing of recognition of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of financial performance.


-end-
View FY20 Third Quarter Financial Schedules & Non-GAAP Reconciliations
View FY20 Third Quarter Earnings Presentation

5


6

MEDTRONIC PLC
WORLD WIDE REVENUE(1)
(Unaudited)
THIRD QUARTERTHIRD QUARTER YEAR-TO-DATE
REPORTEDCONSTANT CURRENCY REPORTEDCONSTANT CURRENCY
(in millions)FY20FY19Growth
Currency Impact(3)
FY20Growth
Organic Growth(4)
FY20FY19Growth
Currency Impact(3)
FY20Growth
Organic Growth(4)
Cardiac & Vascular Group$2,819  $2,786  1.2 %$(18) $2,837  1.8 %1.8 %$8,464  $8,455  0.1 %$(116) $8,580  1.5 %1.5 %
Cardiac Rhythm & Heart Failure1,393  1,397  (0.3) (8) 1,401  0.3  0.3  4,201  4,295  (2.2) (53) 4,254  (1.0) (1.0) 
Coronary & Structural Heart948  913  3.8  (7) 955  4.6  4.6  2,844  2,736  3.9  (47) 2,891  5.7  5.7  
Aortic, Peripheral, & Venous478  476  0.4  (3) 481  1.1  1.1  1,420  1,424  (0.3) (16) 1,436  0.8  0.8  
Minimally Invasive Therapies Group2,176  2,124  2.4  (15) 2,191  3.2  3.2  6,418  6,223  3.1  (95) 6,513  4.7  4.7  
Surgical Innovations1,474  1,434  2.8  (12) 1,486  3.6  3.6  4,345  4,224  2.9  (74) 4,419  4.6  4.6  
Respiratory, Gastrointestinal, & Renal702  690  1.7  (3) 705  2.2  2.2  2,073  1,999  3.7  (21) 2,094  4.8  4.8  
Restorative Therapies Group(2)
2,111  2,026  4.2  (8) 2,119  4.6  3.6  6,235  5,968  4.5  (50) 6,285  5.3  4.7  
Brain Therapies795  732  8.6  (4) 799  9.2  9.2  2,307  2,107  9.5  (23) 2,330  10.6  10.6  
Spine674  655  2.9  (1) 675  3.1  (0.2) 2,023  1,963  3.1  (12) 2,035  3.7  1.8  
Specialty Therapies340  325  4.6  (1) 341  4.9  4.9  996  956  4.2  (8) 1,004  5.0  5.0  
Pain Therapies303  314  (3.5) (1) 304  (3.2) (3.2) 910  942  (3.4) (7) 917  (2.7) (2.7) 
Diabetes Group610  610  —  (5) 615  0.8  0.8  1,798  1,765  1.9  (28) 1,826  3.5  3.5  
TOTAL$7,717  $7,546  2.3 %$(46) $7,763  2.9 %2.6 %$22,916  $22,411  2.3 %$(289) $23,205  3.5 %3.4 %

(1) The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum.
(2) In the first quarter of fiscal year 2020, the Company realigned its divisions within the Restorative Therapies Group, which included a movement of revenue from Transformative Solutions product lines within Specialty Therapies to a product line under Brain Therapies. As a result, fiscal year 2019 results have been recast to adjust for this realignment.
(3) The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates.
(4) Organic growth refers to growth calculated excluding the impact of currency and significant acquisitions (Titan Spine).
7

MEDTRONIC PLC
U.S.(1)(2) REVENUE
(Unaudited)
THIRD QUARTERTHIRD QUARTER YEAR-TO-DATE
REPORTEDREPORTED
(in millions)FY20FY19
Growth		FY20FY19
Growth
Cardiac & Vascular Group$1,366  $1,369  (0.2)%$4,182  $4,240  (1.4)%
Cardiac Rhythm & Heart Failure739  745  (0.8) 2,253  2,334  (3.5) 
Coronary & Structural Heart370  359  3.1  1,149  1,096  4.8  
Aortic, Peripheral, & Venous257  265  (3.0) 780  810  (3.7) 
Minimally Invasive Therapies Group 934  930  0.4  2,769  2,659  4.1  
Surgical Innovations587  589  (0.3) 1,744  1,706  2.2  
Respiratory, Gastrointestinal, & Renal 346  341  1.5  1,025  953  7.6  
Restorative Therapies Group(3)
1,409  1,354  4.1  4,187  4,005  4.5  
Brain Therapies471  440  7.0  1,384  1,279  8.2  
Spine478  459  4.1  1,428  1,359  5.1  
Specialty Therapies243  230  5.7  718  681  5.4  
Pain Therapies217  225  (3.6) 656  686  (4.4) 
Diabetes Group312  348  (10.3) 930  1,006  (7.6) 
TOTAL$4,021  $4,001  0.5 %$12,068  $11,910  1.3 %

(1) U.S. includes the United States and U.S. territories.
(2) The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum.
(3) In the first quarter of fiscal year 2020, the Company realigned its divisions within the Restorative Therapies Group, which included a movement of revenue from Transformative Solutions product lines within Specialty Therapies to a product line under Brain Therapies. As a result, fiscal year 2019 results have been recast to adjust for this realignment.

8

MEDTRONIC PLC
WORLD WIDE REVENUE: GEOGRAPHIC (1)(2)
(Unaudited)
THIRD QUARTERTHIRD QUARTER YEAR-TO-DATE
REPORTEDCONSTANT CURRENCYREPORTEDCONSTANT CURRENCY
(in millions)FY20FY19Growth
Currency Impact(3)
FY20Growth FY20FY19Growth
Currency Impact(3)
FY20Growth
U.S.$1,366  $1,369  (0.2)%$—  $1,366  (0.2)%$4,182  $4,240  (1.4)%$—  $4,182  (1.4)%
Non-U.S. Developed915924(1.0) (11)9260.2  2,7352,766(1.1) (76)2,8111.6  
Emerging Markets5384939.1  (7)54510.5  1,5471,4496.8  (40)1,5879.5  
Cardiac & Vascular Group$2,819  2,7861.2  (18)2,8371.8  8,4648,4550.1  (116)8,5801.5  
U.S.9349300.4  —9340.4  2,7692,6594.1  —2,7694.1  
Non-U.S. Developed791796(0.6) (7)7980.3  2,3642,396(1.3) (59)2,4231.1  
Emerging Markets45139813.3  (8)45915.3  1,2851,16810.0  (36)1,32113.1  
Minimally Invasive Therapies Group2,176  2,1242.4  (15)2,1913.2  6,4186,2233.1  (95)6,5134.7  
U.S.1,4091,3544.1  —1,4094.1  4,1874,0054.5  —4,1874.5  
Non-U.S. Developed4364350.2  (4)4401.1  1,2781,2750.2  (31)1,3092.7  
Emerging Markets26623712.2  (3)26913.5  77068811.9  (19)78914.7  
Restorative Therapies Group 2,111  2,0264.2  (8)2,1194.6  6,2355,9684.5  (50)6,2855.3  
U.S.312348(10.3) —312(10.3) 9301,006(7.6) —930(7.6) 
Non-U.S. Developed23621310.8  (4)24012.7  69361912.0  (23)71615.7  
Emerging Markets634928.6  (1)6430.6  17614025.7  (5)18129.3  
Diabetes Group610610—  (5)6150.8  1,7981,7651.9  (28)1,8263.5  
U.S.4,0214,0010.5  —4,0210.5  12,06811,9101.3  —12,0681.3  
Non-U.S. Developed2,3772,3680.4  (27)2,4041.5  7,0697,0560.2  (189)7,2582.9  
Emerging Markets1,3181,17712.0  (19)1,33713.6  3,7783,4459.7  (100)3,87812.6  
TOTAL$7,717  $7,546  2.3 %$(46) $7,763  2.9 %$22,916  $22,411  2.3 %$(289) $23,205  3.5 %

(1) U.S. includes the United States and U.S. territories. Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries of Western Europe. Emerging Markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as previously defined.
(2) The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum.
(3) The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates.

9

MEDTRONIC PLC
CONSOLIDATED STATEMENTS OF INCOME
(Unaudited) 
 Three months endedNine months ended
(in millions, except per share data)January 24, 2020January 25, 2019January 24, 2020January 25, 2019
Net sales$7,717  $7,546  $22,916  $22,411  
Costs and expenses:  
Cost of products sold2,400  2,265  7,160  6,672  
Research and development expense573  561  1,763  1,736  
Selling, general, and administrative expense2,587  2,596  7,750  7,798  
Amortization of intangible assets436  436  1,317  1,327  
Restructuring charges, net13  26  87  112  
Certain litigation charges108  63  276  166  
Other operating (income) expense, net(39) 57  88  278  
Operating profit1,639  1,542  4,475  4,322  
Other non-operating income, net(96) (71) (305) (309) 
Interest expense156  243  930  726  
Income before income taxes1,579  1,370  3,850  3,905  
Income tax provision(340) 99  (317) 437  
Net income1,919  1,271  4,167  3,468  
Net (income) attributable to noncontrolling interests(4) (2) (24) (9) 
Net income attributable to Medtronic$1,915  $1,269  $4,143  $3,459  
Basic earnings per share$1.43  $0.95  $3.09  $2.57  
Diluted earnings per share$1.42  $0.94  $3.07  $2.54  
Basic weighted average shares outstanding1,340.5  1,342.8  1,340.7  1,348.1  
Diluted weighted average shares outstanding1,351.5  1,352.7  1,351.6  1,359.5  


10

MEDTRONIC PLC
GAAP TO NON-GAAP RECONCILIATIONS
(Unaudited)
 Three months ended January 24, 2020
(in millions, except per share data)Net SalesCost of Products SoldGross Margin PercentOperating ProfitOperating Profit PercentIncome Before Income TaxesNet Income Attributable to Medtronic
Diluted
EPS (1)
Effective Tax Rate
GAAP$7,717  $2,400  68.9 %$1,639  21.2 %$1,579  $1,915  $1.42  (21.5)%
Non-GAAP Adjustments:
Restructuring and associated costs (2)—  (50) 0.6  97  1.3  97  81  0.06  16.5  
Acquisition-related items (3)—  (2) —  28  0.4  28  25  0.02  10.7  
Certain litigation charges—  —  —  108  1.4  108  107  0.08  0.9  
Medical device regulations (5)—  (6) 0.1  13  0.2  13  11  0.01  15.4  
Amortization of intangible assets—  —  —  436  5.6  436  368  0.27  15.6  
Certain tax adjustments, net (6)—  —  —  —  —  —  (558) (0.41) —  
Non-GAAP$7,717  $2,342  69.7 %$2,321  30.1 %$2,261  $1,949  $1.44  13.6 %
Currency impact46  (8) 0.2  (3) (0.2) —  
Currency Adjusted$7,763  $2,334  69.9 %$2,318  29.9 %$1.44  
 Three months ended January 25, 2019
(in millions, except per share data)Net SalesCost of Products SoldGross Margin PercentOperating ProfitOperating Profit PercentIncome Before Income TaxesNet Income Attributable to Medtronic
Diluted
EPS (1)
Effective Tax Rate
GAAP$7,546  $2,265  70.0 %$1,542  20.4 %$1,370  $1,269  $0.94  7.2 %
Non-GAAP Adjustments:
Restructuring and associated costs (2)—  (21) 0.3  66  0.9  66  54  0.04  18.2  
Acquisition-related items (3)—  (1) —  17  0.2  17  12  0.01  29.4  
Certain litigation charges—  —  —  63  0.8  63  51  0.04  19.0  
(Gain)/loss on minority investments (4)—  —  —  —  —  (7) (6) —  14.3  
IPR&D charges (7)—  —  —  11  0.1  11  8  0.01  27.3  
Exit of businesses (8)—  —  —  69  0.9  69  56  0.04  18.8  
Amortization of intangible assets—  —  —  436  5.9  436  371  0.27  14.9  
Certain tax adjustments, net (9)—  —  —  —  —  —  (64) (0.05) —  
Non-GAAP$7,546  $2,243  70.3 %$2,204  29.2 %$2,025  $1,751  $1.29  13.4 %
See description of non-GAAP financial measures at the end of the earnings press release.
(1)The data in this schedule has been intentionally rounded to the nearest $0.01 and, therefore, may not sum.
(2)Associated costs include costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program and consulting expenses.
(3)The charges primarily include costs incurred in connection with legacy-Covidien enterprise resource planning deployment activities, business combination related costs, and changes in the fair value of contingent consideration.
(4)We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations.
(5)The charges represent incremental costs of complying with the new European Union medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses.
(6)The benefit relates to the release of a valuation allowance on certain net operating losses.
(7)The charges were recognized in connection with the impairment of in-process research and development ("IPR&D") assets.
(8)The net charge relates to business exits and is primarily comprised of intangible asset impairments.
(9)The net benefit relates to the impact from U.S. tax reform, intercompany legal entity restructuring, and the finalization of certain income tax aspects of the divestiture of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses within Minimally Invasive Therapies Group on July 29, 2017.
11

MEDTRONIC PLC
GAAP TO NON-GAAP RECONCILIATIONS
(Unaudited)
 Nine months ended January 24, 2020
(in millions, except per share data)Net SalesCost of Products SoldGross Margin PercentOperating ProfitOperating Profit PercentIncome Before Income TaxesNet Income attributable to Medtronic
Diluted
EPS (1)
Effective Tax Rate
GAAP$22,916  $7,160  68.8 %$4,475  19.5 %$3,850  $4,143  $3.07  (8.2)%
Non-GAAP Adjustments:
Restructuring and associated costs (2)—  (117) 0.5  315  1.4  315  268  0.20  14.9  
Acquisition-related items (3)—  (2) —  74  0.3  74  65  0.05  12.2  
Certain litigation charges—  —  —  276  1.2  276  243  0.18  12.0  
(Gain)/loss on minority investments (4)—  —  —  —  —  (11) (9) (0.01) 18.2  
Debt tender premium and other charges (5)—  —  —  (7) —  406  320  0.24  21.2  
Medical device regulations (6)—  (13) 0.1  31  0.1  31  27  0.02  12.9  
Exit of businesses (7)—  —  —  41  0.2  41  35  0.03  14.6  
Contribution to Medtronic Foundation—  —  —  80  0.3  80  62  0.05  22.5  
Amortization of intangible assets—  —  —  1,317  5.7  1,317  1,114  0.82  15.4  
Certain tax adjustments, net (8)—  —  —  —  —  —  (839) (0.62) —  
Non-GAAP$22,916  $7,028  69.3 %$6,602  28.8 %$6,379  $5,429  $4.02  14.5 %
Currency impact289  (37) 0.6  46  (0.2) 0.04  
Currency Adjusted$23,205  $6,991  69.9 %$6,648  28.6 %$4.06  
 Nine months ended January 25, 2019
(in millions, except per share data)Net SalesCost of Products SoldGross Margin PercentOperating ProfitOperating Profit PercentIncome Before Income TaxesNet Income attributable to Medtronic
Diluted
EPS (1)
Effective Tax Rate
GAAP$22,411  $6,672  70.2 %$4,322  19.3 %$3,905  $3,459  $2.54  11.2 %
Non-GAAP Adjustments:
Restructuring and associated costs (2)—  (58) 0.3  256  1.1  256  216  0.16  15.6  
Acquisition-related items (3)—  (5) —  57  0.3  57  44  0.03  22.8  
Certain litigation charges—  —  —  166  0.7  166  142  0.10  14.5  
(Gain)/loss on minority investments (4)—  —  —  —  —  (92) (83) (0.06) 9.8  
IPR&D charges (9)—  —  —  26  0.1  26  23  0.02  11.5  
Exit of business (7)—  —  —  149  0.7  149  118  0.09  20.8  
Amortization of intangible assets—  —  —  1,327  5.9  1,327  1,128  0.83  15.0  
Certain tax adjustments, net (10)—  —  —  —  —  —  (35) (0.03) —  
Non-GAAP$22,411  $6,609  70.5 %$6,303  28.1 %$5,794  $5,012  $3.69  13.3 %
See description of non-GAAP financial measures contained in this release.
(1)The data in this schedule has been intentionally rounded to the nearest $0.01 and, therefore, may not sum.
(2)Associated costs include costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program and consulting expenses.
(3)The charges primarily include costs incurred in connection with legacy-Covidien enterprise resource planning deployment activities, business combination related costs, and changes in fair value of contingent consideration.
(4)We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations.
(5)The charges, which include $413 million recognized in interest expense and ($7 million) recognized in other operating expense, net, primarily related to the early redemption of approximately $5.2 billion of debt.
(6)The charges represent incremental costs of complying with the new European Union medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses.
(7)The net charges relate to the exit of businesses and are primarily comprised of intangible asset impairments.
12

(8)The net benefit primarily relates to the release of a valuation allowance on certain net operating losses and the impact of tax reform in Switzerland and the United States.
(9)The charges were recognized in connection with the impairment of in-process research and development ("IPR&D") assets.
(10) The net benefit relates to the impact of U.S. tax reform, intercompany legal entity restructuring, and the finalization of certain income tax aspects of the divestiture of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses within the Minimally Invasive Therapies Group on July 29, 2017.
13

MEDTRONIC PLC
GAAP TO NON-GAAP RECONCILIATIONS
(Unaudited)
 Three months ended January 24, 2020
(in millions)Net SalesSG&A ExpenseSG&A Expense as a % of Net SalesR&D ExpenseR&D Expense as a % of Net SalesOther Operating (Income) Expense, netOther Operating Expense, net as a % of Net SalesOther Non-Operating Income, net
GAAP$7,717  $2,587  33.5 %$573  7.4 %$(39) (0.5)%$(96) 
Non-GAAP Adjustments:
Restructuring and associated costs (1)—  (34) (0.4) —  —  —  —  —  
Acquisition-related items (2)—  (23) (0.3) —  —  (3) —  —  
Medical device regulations (4)—  —  —  (7) (0.1) —  —  —  
Non-GAAP$7,717  $2,530  32.8 %$566  7.3 %$(42) (0.5)%$(96) 
Currency impact46  11  (0.1) 1  —  46  0.6  —  
Currency Adjusted$7,763  $2,541  32.7 %$567  7.3 %$4  0.1 %$(96) 
See description of non-GAAP financial measures at the end of the earnings press release.
(1)Associated costs include costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program and consulting expenses.
(2)The charges primarily include costs incurred in connection with legacy-Covidien enterprise resource planning deployment activities, business combination related costs, and changes in the fair value of contingent consideration.
(3)We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations.
(4)The charges represent incremental costs of complying with the new European Union medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses.
(5)The net charge relates to the exit of businesses and is primarily comprised of intangible asset impairments.


14

MEDTRONIC PLC
GAAP TO NON-GAAP RECONCILIATIONS
(Unaudited)
 Nine months ended January 24, 2020
(in millions)Net SalesSG&A ExpenseSG&A Expense as a % of Net SalesR&D ExpenseR&D Expense as a % of Net SalesOther Operating (Income) Expense, netOther Operating Expense, net as a % of Net SalesOther Non-Operating Income, net
GAAP$22,916  $7,750  33.8 %$1,763  7.7 %$88  0.4 %$(305) 
Non-GAAP Adjustments:
Restructuring and associated costs (1)—  (111) (0.5) —  —  —  —  —  
Acquisition-related items (2)—  (66) (0.3) —  —  (6) —  —  
(Gain)/loss on minority investments (3)—  —  —  —  —  —  —  11  
Debt tender premium and other charges (4)—  —  —  —  —  7  —  —  
Medical device regulations (5)—  —  —  (18) (0.1) —  —  —  
Exit of businesses (6)—  —  —  —  —  (41) (0.2) —  
Contribution to Medtronic Foundation—  —  —  —  —  (80) (0.3) —  
Non-GAAP$22,916  $7,573  33.0 %$1,745  7.6 %$(32) (0.1)%$(294) 
Currency impact289  85  —  6  (0.1) 190  0.8  —  
Currency Adjusted$23,205  $7,658  33.0 %$1,751  7.5 %$158  0.7 %$(294) 
See description of non-GAAP financial measures at the end of the earnings press release.
(1)Associated costs include costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program and consulting expenses.
(2)The charges primarily include costs incurred in connection with legacy-Covidien enterprise resource planning deployment activities, business combination related costs, and changes in the fair value of contingent consideration.
(3)We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations.
(4)The charges, which include $413 million recognized in interest expense and ($7 million) recognized in other operating expense, net, primarily relate to the early redemption of approximately $5.2 billion of debt.
(5)The charges represent incremental costs of complying with the new European Union medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses.
(6)The net charge relates to the exit of businesses and is primarily comprised of intangible asset impairments.


15

MEDTRONIC PLC
GAAP TO NON-GAAP RECONCILIATIONS
(Unaudited)
Nine months endedThree months endedThree months endedFiscal yearFiscal year
(in millions)January 24, 2020January 24, 2020January 25, 201920192018
Net cash provided by operating activities$5,784  $2,407  $2,055  $7,007  $4,684  
Additions to property, plant, and equipment(877) (293) (302) (1,134) (1,068) 
Free Cash Flow (1)$4,907  $2,114  $1,753  $5,873  $3,616  
See description of non-GAAP financial measures at the end of the earnings press release.

(1)Free cash flow represents operating cash flows less property, plant, and equipment additions.
16

MEDTRONIC PLC
CONSOLIDATED BALANCE SHEETS
(Unaudited)
 
(in millions)January 24, 2020April 26, 2019
ASSETS
Current assets:
Cash and cash equivalents$3,709  $4,393  
Investments7,919  5,455  
Accounts receivable, less allowances of $205 and $190, respectively6,248  6,222  
Inventories, net4,122  3,753  
Other current assets2,045  2,144  
Total current assets24,043  21,967  
Property, plant, and equipment11,507  10,920  
Accumulated depreciation(6,743) (6,245) 
Property, plant, and equipment, net4,764  4,675  
Goodwill40,091  39,959  
Other intangible assets, net19,456  20,560  
Tax assets2,272  1,519  
Other assets2,196  1,014  
Total assets$92,822  $89,694  
LIABILITIES AND EQUITY
Current liabilities:
Current debt obligations$844  $838  
Accounts payable1,945  1,953  
Accrued compensation1,909  2,189  
Accrued income taxes457  567  
Other accrued expenses3,580  2,925  
Total current liabilities8,735  8,472  
Long-term debt24,732  24,486  
Accrued compensation and retirement benefits1,598  1,651  
Accrued income taxes2,738  2,838  
Deferred tax liabilities1,282  1,278  
Other liabilities1,784  757  
Total liabilities40,869  39,482  
Commitments and contingencies
Shareholders’ equity:
Ordinary shares— par value $0.0001, 2.6 billion shares authorized, 1,340,786,042 and 1,340,697,595 shares issued and outstanding, respectively—  —  
Additional paid-in capital26,144  26,532  
Retained earnings28,210  26,270  
Accumulated other comprehensive loss(2,546) (2,711) 
Total shareholders’ equity51,808  50,091  
Noncontrolling interests145  121  
Total equity51,953  50,212  
Total liabilities and equity$92,822  $89,694  

17

MEDTRONIC PLC
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)


 Nine months ended
(in millions)January 24, 2020January 25, 2019
Operating Activities:
Net income$4,167  $3,468  
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization1,991  1,992  
Provision for doubtful accounts67  55  
Deferred income taxes(793) (205) 
Stock-based compensation235  228  
Loss on debt extinguishment406  —  
Other, net140  111  
Change in operating assets and liabilities, net of acquisitions and divestitures:   
Accounts receivable, net(119) (140) 
Inventories, net(346) (367) 
Accounts payable and accrued liabilities103  211  
Other operating assets and liabilities(67) (433) 
Net cash provided by operating activities5,784  4,920  
Investing Activities:
Acquisitions, net of cash acquired(199) (1,615) 
Additions to property, plant, and equipment(877) (799) 
Purchases of investments(8,249) (1,987) 
Sales and maturities of investments5,791  4,159  
Other investing activities(34) (3) 
Net cash used in investing activities(3,568) (245) 
Financing Activities:
Change in current debt obligations, net17  (696) 
Issuance of long-term debt5,568  3  
Payments on long-term debt(5,606) (29) 
Dividends to shareholders(2,170) (2,022) 
Issuance of ordinary shares585  891  
Repurchase of ordinary shares(1,208) (2,728) 
Other financing activities(74) 10  
Net cash used in financing activities(2,888) (4,571) 
Effect of exchange rate changes on cash and cash equivalents(12) (70) 
Net change in cash and cash equivalents(684) 34  
Cash and cash equivalents at beginning of period4,393  3,669  
Cash and cash equivalents at end of period$3,709  $3,703  
Supplemental Cash Flow Information
Cash paid for:
Income taxes$639  $1,206  
Interest348  540  

 EX-101.SCH 3 mdt-20200218.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 mdt-20200218_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 mdt-20200218_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 mdt-20200218_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Ordinary shares, par value $0.0001 per share Common Stock [Member] Cover page. Cover page. Entities [Table] Entities [Table] 0.25% Senior Notes due 2025 Senior Notes 2019 Due 2025 [Member] Senior Notes 2019 Due 2025 [Member] Security Exchange Name Security Exchange Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Registrant Name Entity Registrant Name 1.00% Senior Notes due 2031 Senior Notes 2019 Due 2031, 1.00 Percent [Member] Senior Notes 2019 Due 2031, 1.00 Percent [Member] Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address, Address Line One Entity Address, Address Line One Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Trading Symbol Trading Symbol Pre-commencement Tender Offer Pre-commencement Tender Offer Amendment Flag Amendment Flag Document Period End Date Document Period End Date Country Region Country Region 1.75% Senior Notes due 2049 Senior Notes 2019 Due 2049 [Member] Senior Notes 2019 Due 2049 [Member] 2.250% Senior Notes due 2039 Senior Notes 2019 Due 2039, 2.250 Percent [Member] Senior Notes 2019 Due 2039, 2.250 Percent [Member] Document Type Document Type 0.375% Senior Notes due 2023 Senior Notes 2019 Due 2023, 0.375 Percent [Member] Senior Notes 2019 Due 2023, 0.375 Percent [Member] 0.000% Senior Notes due 2021 Senior Notes 2019 Due 2021 [Member] Senior Notes 2019 Due 2021 [Member] City Area Code City Area Code Class of Stock [Domain] Class of Stock [Domain] Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, City or Town Entity Address, City or Town 1.625% Senior Notes due 2031 Senior Notes 2019 Due 2031, 1.625 Percent [Member] Senior Notes 2019 Due 2031, 1.625 Percent [Member] 0.000% Senior Notes due 2022 Senior Notes 2019 Due 2022 [Member] Senior Notes 2019 Due 2022 [Member] Entity Central Index Key Entity Central Index Key 1.50% Senior Notes due 2039 Senior Notes 2019 Due 2039, 1.50 Percent [Member] Senior Notes 2019 Due 2039, 1.50 Percent [Member] Floating Rate Notes due 2021 Senior Notes 2019 Due 2021, Floating [Member] Senior Notes 2019 Due 2021, Floating [Member] Entity Information [Line Items] Entity Information [Line Items] Entity Address, Country Entity Address, Country 1.125% Senior Notes due 2027 Senior Notes 2019 Due 2027 [Member] Senior Notes 2019 Due 2027 [Member] Title of 12(b) Security Title of 12(b) Security Class of Stock [Axis] Class of Stock [Axis] EX-101.PRE 7 mdt-20200218_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 8 mdtlogo2a951.jpg MDT LOGO begin 644 mdtlogo2a951.jpg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end XML 10 mdt-20200218_htm.xml IDEA: XBRL DOCUMENT 0001613103 2020-02-18 2020-02-18 0001613103 us-gaap:CommonStockMember 2020-02-18 2020-02-18 0001613103 mdt:SeniorNotes2019Due2021FloatingMember 2020-02-18 2020-02-18 0001613103 mdt:SeniorNotes2019Due2021Member 2020-02-18 2020-02-18 0001613103 mdt:SeniorNotes2019Due2022Member 2020-02-18 2020-02-18 0001613103 mdt:SeniorNotes2019Due20230.375PercentMember 2020-02-18 2020-02-18 0001613103 mdt:SeniorNotes2019Due2025Member 2020-02-18 2020-02-18 0001613103 mdt:SeniorNotes2019Due2027Member 2020-02-18 2020-02-18 0001613103 mdt:SeniorNotes2019Due20311.625PercentMember 2020-02-18 2020-02-18 0001613103 mdt:SeniorNotes2019Due20311.00PercentMember 2020-02-18 2020-02-18 0001613103 mdt:SeniorNotes2019Due20392.250PercentMember 2020-02-18 2020-02-18 0001613103 mdt:SeniorNotes2019Due20391.50PercentMember 2020-02-18 2020-02-18 0001613103 mdt:SeniorNotes2019Due2049Member 2020-02-18 2020-02-18 0001613103 Medtronic plc D02 XH02 false 8-K 2020-02-18 L2 1-36820 98-1183488 20 On Hatch, Lower Hatch Street Dublin 2 IE 353 1 438-1700 false false false false Ordinary shares, par value $0.0001 per share MDT NYSE Floating Rate Notes due 2021 MDT/21 NYSE 0.000% Senior Notes due 2021 MDT/21A NYSE 0.000% Senior Notes due 2022 MDT/22B NYSE 0.375% Senior Notes due 2023 MDT/23B NYSE 0.25% Senior Notes due 2025 MDT/25 NYSE 1.125% Senior Notes due 2027 MDT/27 NYSE 1.625% Senior Notes due 2031 MDT/31 NYSE 1.00% Senior Notes due 2031 MDT/31A NYSE 2.250% Senior Notes due 2039 MDT/39A NYSE 1.50% Senior Notes due 2039 MDT/39B NYSE 1.75% Senior Notes due 2049 MDT/49 NYSE false XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Document And Entity Information
Feb. 18, 2020
Entity Information [Line Items]  
Document Type 8-K
Document Period End Date Feb. 18, 2020
Entity Registrant Name Medtronic plc
Entity Incorporation, State or Country Code L2
Entity File Number 1-36820
Entity Tax Identification Number 98-1183488
Entity Address, Address Line One 20 On Hatch, Lower Hatch Street
Entity Address, City or Town Dublin 2
Entity Address, Country IE
Entity Address, Postal Zip Code D02 XH02
Country Region 353
City Area Code 1
Local Phone Number 438-1700
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001613103
Ordinary shares, par value $0.0001 per share  
Entity Information [Line Items]  
Title of 12(b) Security Ordinary shares, par value $0.0001 per share
Trading Symbol MDT
Security Exchange Name NYSE
Floating Rate Notes due 2021  
Entity Information [Line Items]  
Title of 12(b) Security Floating Rate Notes due 2021
Trading Symbol MDT/21
Security Exchange Name NYSE
0.000% Senior Notes due 2021  
Entity Information [Line Items]  
Title of 12(b) Security 0.000% Senior Notes due 2021
Trading Symbol MDT/21A
Security Exchange Name NYSE
0.000% Senior Notes due 2022  
Entity Information [Line Items]  
Title of 12(b) Security 0.000% Senior Notes due 2022
Trading Symbol MDT/22B
Security Exchange Name NYSE
0.375% Senior Notes due 2023  
Entity Information [Line Items]  
Title of 12(b) Security 0.375% Senior Notes due 2023
Trading Symbol MDT/23B
Security Exchange Name NYSE
0.25% Senior Notes due 2025  
Entity Information [Line Items]  
Title of 12(b) Security 0.25% Senior Notes due 2025
Trading Symbol MDT/25
Security Exchange Name NYSE
1.125% Senior Notes due 2027  
Entity Information [Line Items]  
Title of 12(b) Security 1.125% Senior Notes due 2027
Trading Symbol MDT/27
Security Exchange Name NYSE
1.625% Senior Notes due 2031  
Entity Information [Line Items]  
Title of 12(b) Security 1.625% Senior Notes due 2031
Trading Symbol MDT/31
Security Exchange Name NYSE
1.00% Senior Notes due 2031  
Entity Information [Line Items]  
Title of 12(b) Security 1.00% Senior Notes due 2031
Trading Symbol MDT/31A
Security Exchange Name NYSE
2.250% Senior Notes due 2039  
Entity Information [Line Items]  
Title of 12(b) Security 2.250% Senior Notes due 2039
Trading Symbol MDT/39A
Security Exchange Name NYSE
1.50% Senior Notes due 2039  
Entity Information [Line Items]  
Title of 12(b) Security 1.50% Senior Notes due 2039
Trading Symbol MDT/39B
Security Exchange Name NYSE
1.75% Senior Notes due 2049  
Entity Information [Line Items]  
Title of 12(b) Security 1.75% Senior Notes due 2049
Trading Symbol MDT/49
Security Exchange Name NYSE
ZIP 15 0001613103-20-000002-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001613103-20-000002-xbrl.zip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end JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mdt-20200218.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 13, "dts": { "calculationLink": { "local": [ "mdt-20200218_cal.xml" ] }, "definitionLink": { "local": [ "mdt-20200218_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "mdt-20200218.htm" ] }, "labelLink": { "local": [ "mdt-20200218_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "mdt-20200218_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "mdt-20200218.xsd" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 40, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 11, "memberStandard": 1, "nsprefix": "mdt", "nsuri": "http://www.medtronic.com/20200218", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mdt-20200218.htm", "contextRef": "iba3653eda26e4308a677cc64c96c26bb_D20200218-20200218", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Document And Entity Information", "role": "http://www.medtronic.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mdt-20200218.htm", "contextRef": "iba3653eda26e4308a677cc64c96c26bb_D20200218-20200218", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 12, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region code of country", "label": "Country Region", "terseLabel": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page.", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Information [Line Items]", "terseLabel": "Entity Information [Line Items]" } } }, "localname": "EntityInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "mdt_SeniorNotes2019Due2021FloatingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes 2019 Due 2021, Floating [Member]", "label": "Senior Notes 2019 Due 2021, Floating [Member]", "terseLabel": "Floating Rate Notes due 2021" } } }, "localname": "SeniorNotes2019Due2021FloatingMember", "nsuri": "http://www.medtronic.com/20200218", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "mdt_SeniorNotes2019Due2021Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes 2019 Due 2021 [Member]", "label": "Senior Notes 2019 Due 2021 [Member]", "terseLabel": "0.000% Senior Notes due 2021" } } }, "localname": "SeniorNotes2019Due2021Member", "nsuri": "http://www.medtronic.com/20200218", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "mdt_SeniorNotes2019Due2022Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes 2019 Due 2022 [Member]", "label": "Senior Notes 2019 Due 2022 [Member]", "terseLabel": "0.000% Senior Notes due 2022" } } }, "localname": "SeniorNotes2019Due2022Member", "nsuri": "http://www.medtronic.com/20200218", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "mdt_SeniorNotes2019Due20230.375PercentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes 2019 Due 2023, 0.375 Percent [Member]", "label": "Senior Notes 2019 Due 2023, 0.375 Percent [Member]", "terseLabel": "0.375% Senior Notes due 2023" } } }, "localname": "SeniorNotes2019Due20230.375PercentMember", "nsuri": "http://www.medtronic.com/20200218", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "mdt_SeniorNotes2019Due2025Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes 2019 Due 2025 [Member]", "label": "Senior Notes 2019 Due 2025 [Member]", "terseLabel": "0.25% Senior Notes due 2025" } } }, "localname": "SeniorNotes2019Due2025Member", "nsuri": "http://www.medtronic.com/20200218", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "mdt_SeniorNotes2019Due2027Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes 2019 Due 2027 [Member]", "label": "Senior Notes 2019 Due 2027 [Member]", "terseLabel": "1.125% Senior Notes due 2027" } } }, "localname": "SeniorNotes2019Due2027Member", "nsuri": "http://www.medtronic.com/20200218", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "mdt_SeniorNotes2019Due20311.00PercentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes 2019 Due 2031, 1.00 Percent [Member]", "label": "Senior Notes 2019 Due 2031, 1.00 Percent [Member]", "terseLabel": "1.00% Senior Notes due 2031" } } }, "localname": "SeniorNotes2019Due20311.00PercentMember", "nsuri": "http://www.medtronic.com/20200218", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "mdt_SeniorNotes2019Due20311.625PercentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes 2019 Due 2031, 1.625 Percent [Member]", "label": "Senior Notes 2019 Due 2031, 1.625 Percent [Member]", "terseLabel": "1.625% Senior Notes due 2031" } } }, "localname": "SeniorNotes2019Due20311.625PercentMember", "nsuri": "http://www.medtronic.com/20200218", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "mdt_SeniorNotes2019Due20391.50PercentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes 2019 Due 2039, 1.50 Percent [Member]", "label": "Senior Notes 2019 Due 2039, 1.50 Percent [Member]", "terseLabel": "1.50% Senior Notes due 2039" } } }, "localname": "SeniorNotes2019Due20391.50PercentMember", "nsuri": "http://www.medtronic.com/20200218", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "mdt_SeniorNotes2019Due20392.250PercentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes 2019 Due 2039, 2.250 Percent [Member]", "label": "Senior Notes 2019 Due 2039, 2.250 Percent [Member]", "terseLabel": "2.250% Senior Notes due 2039" } } }, "localname": "SeniorNotes2019Due20392.250PercentMember", "nsuri": "http://www.medtronic.com/20200218", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "mdt_SeniorNotes2019Due2049Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes 2019 Due 2049 [Member]", "label": "Senior Notes 2019 Due 2049 [Member]", "terseLabel": "1.75% Senior Notes due 2049" } } }, "localname": "SeniorNotes2019Due2049Member", "nsuri": "http://www.medtronic.com/20200218", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Common Stock [Member]", "terseLabel": "Ordinary shares, par value $0.0001 per share" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.medtronic.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 17 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 18 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 13 96 1 false 12 0 false 0 false false R1.htm 0001001 - Document - Document And Entity Information Sheet http://www.medtronic.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports mdt-20200218.htm exhibit991-fy20q3earni.htm mdt-20200218.xsd mdt-20200218_cal.xml mdt-20200218_def.xml mdt-20200218_lab.xml mdt-20200218_pre.xml http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true true